This Week at FDA: Prasad’s exit from CBER, 7-OH scheduling, updated opioid labeling

This Week at FDAThis Week at FDABiologics/ biosimilars/ vaccinesCBERGovernment/legislationLeadershipMDUFAMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)